Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing & Reimbursement

Set Alert for Pricing & Reimbursement

Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List

Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.

Pricing Debate Pricing Strategies

Pharma Execs Urge 'Balance' In China Payer Price Negotiations

The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.

China Pricing Strategies

Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab

The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab. 

Neurology Market Access

Vision Possible: Why Eyestem Is 'Bullish' About Its Dry AMD Candidate

Eyestem founder and CEO talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.

Research & Development Regenerative Medicine

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

Biosimilars Market Access

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Business Strategies Commercial

CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure

Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody. 

Clinical Trials Neurology

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization

Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit.

Leadership Pricing Debate

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

Gastrointestinal Market Access

Industry Improving On LMIC Drug Access Plans But Tropical Disease R&D Lacking

The non-profit Access To Medicine Foundation’s latest report shows big pharma is making progress on drug access plans as new non-exclusive voluntary licences help facilitate sustainable supply, but there is still not enough R&D for tropical diseases.

Companies Market Access

EQRx Confronts US Drug Development Realities, Shifts Pricing Approach

Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.

Business Strategies Pricing Strategies

Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches

Amgen will be first to launch a Humira biosimilar in the US with its Amgevita, but it and other adalimumab copies may add pressure to the company’s already declining top-seller Enbrel.

Biosimilars Market Access
See All
UsernamePublicRestriction

Register